Sun Pharma-Ranbaxy deal gets nod from BSE, NSE

22 Jul 2014 Evaluate

The two leading stock exchanges -- BSE and NSE -- have given clearance to $4-billion merger of Ranbaxy Laboratories with Sun Pharmaceutical Industries. The ‘no-objection’ from the two exchanges would allow both the entities to file their scheme of amalgamation with the High Court for further clearance of the deal and marks one of the numerous regulatory approvals that Sun Pharma and Ranbaxy need to consummate for the transaction.

The deal had separately come under scanner of the markets regulator SEBI for alleged insider trading violations and the present ‘no-objection’ from the exchanges.

The combination of Sun Pharma and Ranbaxy creates the fifth-largest speciality generics company in the world and the largest pharmaceutical company in India. The two firms now need clearances of the High Court and the Competition Commission of India (CCI), among others.

Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.

Sun Pharma Inds. Share Price

1716.40 -1.10 (-0.06%)
30-Dec-2025 11:23 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1716.40
Dr. Reddys Lab 1268.25
Cipla 1487.35
Zydus Lifesciences 902.25
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×